Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

Prior treatment

• Concomitant treatment with any systemic immunosuppressive drug

Other illness

• Diagnosis with a coagulation disorder other than haemophilia A

Other

• Participation in an interventional clinical trial during the time period evaluated
• Participation in another non-interventional study of Octapharma

• Male and female patients of any age and ethnicity
• Severe haemophilia A (FVIII:C\<1%)
• Decision to prescribe Octapharma's FVIII concentrate before enrollment into the study
• Either
• No previous treatment with FVIII concentrates or other blood products containing FVIII (PUPs) OR
• Less than 5 Exposure Days (EDs) to FVIII concentrates or other blood products containing FVIII (MTPs), if
• data are available on all previous treatment, AND
• they did not develop an inhibitor at any time point, OR
• they developed an inhibitor during treatment with an Octapharma FVIII concentrate AND continue treatment with THIS Octapharma FVIII concentrate (in the presence or absence of emicizumab).
• Voluntarily given, fully informed written and signed consent obtained before any study-related data documentation is conducted (obtained from the patient's parent/legal guardian)